BRA
AZN icon

Bender Robert & Associates’s AstraZeneca AZN Stock Holding History

Bender Robert & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,438
Closed -$1.32M – 46
2024
Q2 		$1.32M Buy
+8,438
New +$1.27M 0.29% 25

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Bender Robert & Associates's AZN Position: Q1 2025 in Review

Bender Robert & Associates sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 6,101 shares — an estimated $799K sold.

Bender Robert & Associates first reported a position in AZN in Q3 2021 and held it in 13 quarters. The position peaked at $3.07M in Q1 2022. 1,250 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Bender Robert & Associates reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Bender Robert & Associates sold 6,101 AstraZeneca shares in Q1 2025, an estimated $799K.
  • Bender Robert & Associates first reported a position in AstraZeneca in Q3 2021 and held it in 13 quarters.
  • Bender Robert & Associates's AstraZeneca position peaked at $3.07M in Q1 2022.
  • 1,250 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Bender Robert & Associates's 13F filing for Q1 2025, filed 18 Apr 2025.